NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ

$32.11

+0.75%
HealthcareBiotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

At a Glance

Live Snapshot
Market Cap$3.75B
EPS-1.7500
P/E Ratio-18.35
Earnings Date08/05/2026

nams

Investments in Property, Plant, and Equipment

Last Annual Value

-246.00K

3-Year CAGR

-4%

5-Year CAGR

-73%

10-Year CAGR

-31%

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. Competitors Analysis of Investments in Property, Plant, and Equipment

NAMS · NASDAQ
CompanyInvestments in Property, Plant, and Equipment
CAGR 3Y
CAGR 5Y
CAGR 10Y
-246.00K
N/AN/AN/A 
-56.00K
N/AN/AN/A
ACLX logo
Arcellx, Inc.
NASDAQ:ACLX
-2.33M
N/AN/AN/A
-999.00K
N/AN/AN/A
-134.00K
N/AN/AN/A
-5.76M
N/AN/AN/A
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
-8.00K
N/AN/AN/A
-1.45M
N/AN/AN/A
-11.31M
N/AN/AN/A
0.00
N/AN/AN/A
-73.00K
N/AN/AN/A
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. Fair Value Envelope

NAMS · NASDAQ

Our analysis suggests that NAMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.11, this represents a potential HIDDEN relative to our calculated worth for NewAmsterdam Pharma Company N.V..

Intrinsic Value
Current Price: $32.11